These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22220307)

  • 1. Pharmacodynamics of bisphosphonates in arthritis.
    Le Goff B; Heymann D
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):633-41. PubMed ID: 22220307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
    Suzuki Y
    Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
    Herrak P; Görtz B; Hayer S; Redlich K; Reiter E; Gasser J; Bergmeister H; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2004 Jul; 50(7):2327-37. PubMed ID: 15248234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL; Fornasier TL; Bogoch TR
    J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological effects of bisphosphonates in patients with rheumatoid arthritis].
    Nagashima M; Shu G; Yamamoto K
    Nihon Rinsho; 2005 Sep; 63(9):1607-12. PubMed ID: 16164219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates use in children.
    Sebestyen JF; Srivastava T; Alon US
    Clin Pediatr (Phila); 2012 Nov; 51(11):1011-24. PubMed ID: 22935217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
    Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
    J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER; Löwik CW; Papapoulos SE
    Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
    Romas E
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B; Ling Chau JF; Wang X; Leong WF
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
    Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis.
    Garimella MG; Kour S; Piprode V; Mittal M; Kumar A; Rani L; Pote ST; Mishra GC; Chattopadhyay N; Wani MR
    J Immunol; 2015 Dec; 195(11):5136-48. PubMed ID: 26538398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.